Results 11 to 20 of about 3,657 (192)

Molecular Mechanisms of Resistance and Treatment Efficacy of Delamanid Against Mycobacterium tuberculosis: A Systematic Review [PDF]

Health Science Reports
Background and Aims Tuberculosis (TB) remains a major global health problem, and treatment progress is increasingly threatened by rising multidrug‐resistant tuberculosis (MDR‐TB). Delamanid (DLM), a nitroimidazole drug, has shown good efficacy and safety
Md. Mahmudul Islam, Md. Zahid Hasan, Md. Touki Tahamid Tusar, Md. Yeamin Hossain, Md. Motaher Hossain, Md. Abdulla Al Jubayed, Md. Jubaer‐Al‐Abedin, Sheikh Soikot, Shanzida Akther, Jahid Bhuyian, Hafizur Rahman Gazi, B. M. Mahmudul Hasan, Md. Shofiul Azam, Md. Enamul Haque, Abdullah‐Al‐Jubayer, Md. Faruk Hasan, F. M. Ali Haydar, Md. Khalekuzzaman, Md. Torequl Islam, Sohel Hasan   +19 more
doaj   +3 more sources

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis [PDF]

eLife, 2016
There is an urgent requirement for safe, oral and cost-effective drugs for the treatment of visceral leishmaniasis (VL). We report that delamanid (OPC-67683), an approved drug for multi-drug resistant tuberculosis, is a potent inhibitor of Leishmania ...
Stephen Patterson, Susan Wyllie, Suzanne Norval, Laste Stojanovski, Frederick RC Simeons, Jennifer L Auer, Maria Osuna-Cabello, Kevin D Read, Alan H Fairlamb   +8 more
doaj   +2 more sources

Six-Month Response to Delamanid Treatment in MDR TB Patients

Emerging Infectious Diseases, 2017
Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing ...
Cathy Hewison, Gabriella Ferlazzo, Zaza Avaliani, Armen Hayrapetyan, Sylvie Jonckheere, Zarema Khaidarkhanova, Erika Mohr, Animesh Sinha, Alena Skrahina, Debrah Vambe, Irina Vasilyeva, Nathalie Lachenal, Francis Varaine   +12 more
doaj   +2 more sources

Solid Lipid Nanoparticles Enhancing the Leishmanicidal Activity of Delamanid [PDF]

Pharmaceutics, 2023
Leishmaniasis, a zoonotic parasitic disease transmitted by infected sandflies, impacts nearly 1 million people yearly and is endemic in many countries across Asia, Africa, the Americas, and the Mediterranean; despite this, it remains a neglected disease with limited effective treatments, particularly in impoverished communities with limited access to ...
Javier Santamaría-Aguirre, Daniela Jacho, Miguel A. Méndez, Ana Poveda, Javier Carrión, Mónica L. Fanarraga   +5 more
openaire   +8 more sources

Comparison of Individual Regimen Containing Bedaquiline with Delamanid and Bedaquiline without Delamanid on Efficacy and Safety in Multidrug-resistant Tuberculosis Patients: Implementation in Dr. Soetomo General Academic Hospital, Indonesia

International Journal of Mycobacteriology
Background: Bedaquiline is one of the core drugs used to treat multidrug-resistant TB (MDR-TB). Delamanid is one of the companion drugs in group C which is used to complete the treatment regimen when drugs in groups A and B can not be used.
Soedarsono Soedarsono, Ni Made Mertaniasih, Tutik Kusmiati, Ariani Permatasari, Susi Subay, Suko Hari Adiono   +5 more
doaj   +2 more sources

Clinical outcomes of multidrug-resistant tracheobronchial tuberculosis receiving anti-tuberculosis regimens containing bedaquiline or delamanid

Scientific Reports
The treatment of multidrug-resistant tracheobronchial tuberculosis poses challenges, and research investigating the efficacy of bedaquiline or delamanid as treatment for this condition is limited.
Qing Chen, Tao Huang, Liping Zou, Xianzhen Tang, Zhengyu Shi, Xinwei Wang, Huaige Wu, Jiying Sun, Xiaoli Lu, Li Liang, Liangshuang Jiang, Dafeng Liu, Shenjie Tang, Guihui Wu, Wei He   +14 more
doaj   +2 more sources

Delamanid for Multidrug-Resistant Pulmonary Tuberculosis [PDF]

New England Journal of Medicine, 2012
Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis.In this randomized, placebo-controlled, multinational clinical trial, we assigned 481 patients (nearly
Maria Tarcela, Gler, Vija, Skripconoka, Epifanio, Sanchez-Garavito, Heping, Xiao, Jose L, Cabrera-Rivero, Dante E, Vargas-Vasquez, Mengqiu, Gao, Mohamed, Awad, Seung-Kyu, Park, Tae Sun, Shim, Gee Young, Suh, Manfred, Danilovits, Hideo, Ogata, Anu, Kurve, Joon, Chang, Katsuhiro, Suzuki, Thelma, Tupasi, Won-Jung, Koh, Barbara, Seaworth, Lawrence J, Geiter, Charles D, Wells   +20 more
openaire   +4 more sources

Experience of Using Delamanid in the Treatment of Multiple Drug Resistant Tuberculosis

Туберкулез и болезни лёгких
The objective: to evaluate treatment results in MDR TB patients when delamanid is added to the treatment regimen.Subjects and Methods. 91 patients with multiple drug resistant pulmonary tuberculosis were included in the study, of which 36 people (39.6 ...
T. R. Bagdasaryan, M. A. Plekhanova, V. Yu. Smirnov, E. A. Grigorieva, Yu. I. Timakova, A. S. Goncharov   +5 more
doaj   +2 more sources

Drug resistance to delamanid was detected in susceptible tuberculosis patient in Russia

Journal of Global Antimicrobial Resistance
AIM: To detect mutations in M. tuberculosis (MTB) associated with delamanid drug resistance in patients with tuberculosis (TB) in Russia. BACKGROUND: Delamanid is important in treatment of multi- and extensively drug-resistant TB.
Platon Eliseev, Irina Vasilyeva, Anatoly Vinokurov, Evgeny Kuznetsov, Kirill Baibekov, Anastasia Kazulina, Anastasia Samoilova   +6 more
doaj   +2 more sources

Delamanid-containing regimens over 24 weeks for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis: preliminary results from a single center in a multicenter, prospective, observational study [PDF]

Frontiers in Medicine
BackgroundSingle center preliminary results from a multicenter, prospective, observational study whose aims were to investigate the efficacy and safety of 24-week delamanid-containing regimens in Chinese multidrug-resistant/rifampicin-resistant ...
Fuping Yang, Mingdan Yin, Xingmei Jiang, Xing Zhao, Xuemei An, Yan Liu, Yijia Yuan   +6 more
doaj   +2 more sources